Inhibition of complement factor C5a or C5aR for cholesterol crystal embolism–related vascular thrombosis with microvascular injury and its consequences
A randomized, open-label, clinical trial examined the effects of canagliflozin on albuminuria and eGFR decline using an individual pre-intervention eGFR slope
Corrigendum to “Early treatment with xenon protects against the cold ischemia associated with chronic allograft nephropathy in rats.� Kidney International 2013;85:112–123